1-4 of 4
Andrew B. Nixon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, Kelli Hammond, Federica Marmorino, Daniele Rossini, Richard M. Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T. Moore, Michael S. Lee, Hanna K. Sanoff, Federico Innocenti, Andrew B. Nixon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2146–2154.
https://doi.org/10.1158/1535-7163.MCT-20-0249
Published: 02 October 2020
View article titled, Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Open the PDF for Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib in another window
Includes: Supplementary data
Journal Articles

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105

Yingmiao Liu, Mark D. Starr, John C. Brady, Christel Rushing, Herbert Pang, Bonne Adams, Delia Alvarez, Charles P. Theuer, Herbert I. Hurwitz, Andrew B. Nixon
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (10): 2248–2256.
https://doi.org/10.1158/1535-7163.MCT-17-0916
Published: 01 October 2018
View article titled, Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Open the PDF for Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 in another window
Includes: Supplementary data
Journal Articles

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

Yingmiao Liu, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, Anthony Amara, Ivy Altomare, Hope E. Uronis, Herbert I. Hurwitz, Andrew B. Nixon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (4): 1048–1056.
https://doi.org/10.1158/1535-7163.MCT-14-0923-T
Published: 09 April 2015
View article titled, Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Open the PDF for Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus in another window
Includes: Supplementary data
Journal Articles

Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery

Tina D. Tailor, Gabi Hanna, Pavel S. Yarmolenko, Matthew R. Dreher, Allison S. Betof, Andrew B. Nixon, Ivan Spasojevic, Mark W. Dewhirst
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1798–1808.
https://doi.org/10.1158/1535-7163.MCT-09-0856
Published: 09 June 2010
View article titled, Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Open the PDF for Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery in another window